Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis.

Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis.
复制标题

DOI:
10.1038/tp.2017.124
复制
发表时间:
2017-06-06
影响因子:
6.8
通讯作者:
McGuire P
McGuire P
中科院分区:
医学1区
文献类型:
--
作者:
Egerton A;Modinos G;Ferrera D;McGuire P

文献摘要

参考文献

被引文献

相似文献

来自动物模型和尸检研究的数据表明,精神分裂症与大脑 GABA 能功能障碍有关。精神分裂症中 GABA 功能的体内研究数据在多大程度上反映了这一点尚不清楚。对 Medline 数据库进行了检索,找出截至 2016 年 10 月 21 日发表的文章。检索词包括 GABA、质子磁共振波谱 (1H-MRS)、正电子发射断层扫描 (PET)、单光子发射计算机断层扫描 (SPECT)、精神分裂症和精神病。确定了 16 项 GABA 1H-MRS 研究(538 名对照,526 名患者)和 7 项关于 GABAA/苯二氮卓受体 (GABAA/BZR) 可用性的 PET/SPECT 研究(118 名对照,113 名患者)。内侧前额皮质 (mPFC)、顶叶/枕叶皮质 (POC) 和纹状体 1H-MRS GABA 的荟萃分析未显示显着的组间差异(mFC:g=-0.3,409 名患者,495 名对照,95% 置信区间 (CI):-0.6 至 0.1;POC:g=-0.3,139 名患者,111 名对照, 95% CI:-0.9 至 0.3;纹状体:g=-0.004,123 名患者,95 名对照,95% CI:-0.7 至 0.7)。研究之间的异质性很高(I2>50%),随后的调节或荟萃回归分析无法解释这一点。没有足够的 PET/SPECT 受体可用性研究来进行荟萃分析,但系统评价并未表明区域 GABAA/BZR 可用性存在可复制的组间差异。目前的文献并未揭示精神分裂症患者体内 GABA 神经影像学指标的一致改变,正如动物模型和尸检数据所推测的那样。该分析强调需要通过改进方法和解决异质性的潜在来源来进一步进行 GABA 神经影像研究。
Data from animal models and from postmortem studies suggest that schizophrenia is associated with brain GABAergic dysfunction. The extent to which this is reflected in data from in vivo studies of GABA function in schizophrenia is unclear. The Medline database was searched to identify articles published until 21 October 2016. The search terms included GABA, proton magnetic resonance spectroscopy (1H-MRS), positron emission tomography (PET), single photon emission computed tomography (SPECT), schizophrenia and psychosis. Sixteen GABA 1H-MRS studies (538 controls, 526 patients) and seven PET/SPECT studies of GABAA/benzodiazepine receptor (GABAA/BZR) availability (118 controls, 113 patients) were identified. Meta-analyses of 1H-MRS GABA in the medial prefrontal cortex (mPFC), parietal/occipital cortex (POC) and striatum did not show significant group differences (mFC: g=−0.3, 409 patients, 495 controls, 95% confidence interval (CI): −0.6 to 0.1; POC: g=−0.3, 139 patients, 111 controls, 95% CI: −0.9 to 0.3; striatum: g=−0.004, 123 patients, 95 controls, 95% CI: −0.7 to 0.7). Heterogeneity across studies was high (I2>50%), and this was not explained by subsequent moderator or meta-regression analyses. There were insufficient PET/SPECT receptor availability studies for meta-analyses, but a systematic review did not suggest replicable group differences in regional GABAA/BZR availability. The current literature does not reveal consistent alterations in in vivo GABA neuroimaging measures in schizophrenia, as might be hypothesized from animal models and postmortem data. The analysis highlights the need for further GABA neuroimaging studies with improved methodology and addressing potential sources of heterogeneity.
DOI: 10.1176/appi.ajp.2015.14081031
发表时间: 2015-11-01
期刊: The American journal of psychiatry
影响因子: --
作者:
Frankle WG;Cho RY;Prasad KM;Mason NS;Paris J;Himes ML;Walker C;Lewis DA;Narendran R
通讯作者: Narendran R
DOI: 10.1016/0306-4522(96)00328-4
发表时间: 1996-12-01
期刊: NEUROSCIENCE
影响因子: 3.3
作者:
Benes, FM;Vincent, SL;Khan, Y
通讯作者: Khan, Y
DOI: 10.1016/s0891-0618(00)00105-8
发表时间: 2000-12-01
影响因子: 2.8
作者:
Benes, FM;Todtenkopf, MS;Williams, M
通讯作者: Williams, M
DOI: 10.1001/archpsyc.59.9.851
发表时间: 2002-09-01
影响因子: --
作者:
Epperson, CN;Haga, K;Krystal, JH
通讯作者: Krystal, JH
DOI: 10.1016/0197-2456(86)90046-2
发表时间: 1986-09-01
期刊: CONTROLLED CLINICAL TRIALS
影响因子: --
作者:
DERSIMONIAN, R;LAIRD, N
通讯作者: LAIRD, N